Table 3 Subsequent treatments after disease relapse
Group | Erlotinib group (n = 32) | GC group (n = 33) | Total (n = 65) |
|---|---|---|---|
With subsequent treatments | 23 (71.9) | 27 (81.8) | 50 (76.9) |
Targeted therapy | 15 (46.9) | 23 (69.7) | 38 (58.5) |
Other treatments | 8 (25.0) | 4 (12.1) | 12 (18.4) |
Without subsequent treatments | 9 (28.1) | 6 (18.2) | 15 (23.1) |
Total, n (%) | 32 (100.0) | 33 (100.0) | 65 (100.0) |
